16

 · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 2:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 3:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 4:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 5:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 6:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 7:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 8:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 9:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 10:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 11:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 12:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 13:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 14:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 15:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is
Page 16:  · As a leader in the HIV treatment market, Gilead provides drugs to eight out of every ten HIV treatment-naïve patients in the United States. An HIV treatment-naïve patient is